Genentech and Curis' vismodegib is submitted for FDA OK

09/12/2011 | Xconomy

Roche Holding unit Genentech is seeking FDA approval of vismodegib, a skin cancer drug developed with Curis. Clinical data show that vismodegib significantly reduces tumors in patients with basal cell carcinoma. The oral treatment works by disrupting the hedgehog biological pathway.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA